{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T07:41:43Z","timestamp":1792395703347,"version":"4.4.0"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M752837"],"award-info":[{"award-number":["2024M752837"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82504649"],"award-info":[{"award-number":["82504649"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473824"],"award-info":[{"award-number":["82473824"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008990","name":"Zhejiang Province Science and Technology Department","doi-asserted-by":"publisher","award":["2025C01123"],"award-info":[{"award-number":["2025C01123"]}],"id":[{"id":"10.13039\/501100008990","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008990","name":"Zhejiang Province Science and Technology Department","doi-asserted-by":"publisher","award":["2025C01189"],"award-info":[{"award-number":["2025C01189"]}],"id":[{"id":"10.13039\/501100008990","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Zhejiang Province Natural Science Foundation","doi-asserted-by":"publisher","award":["LR26H300001"],"award-info":[{"award-number":["LR26H300001"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.molmed.2026.09.014","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:15:00Z","timestamp":1792214100000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Degradation-coupled antibody conjugates for precision cancer therapy"],"prefix":"10.1016","author":[{"given":"Xinlei","family":"Zhuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqiang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2026.09.014_bb0005","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.annonc.2023.12.001","article-title":"Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)","volume":"35","author":"Saura","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.molmed.2026.09.014_bb0010","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molmed.2026.09.014_bb0015","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.molmed.2026.09.014_bb0020","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molmed.2026.09.014_bb0025","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S1470-2045(25)00021-X","article-title":"Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor \u03b1-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial","volume":"26","author":"Van Gorp","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molmed.2026.09.014_bb0030","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.annonc.2025.12.017","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study","volume":"37","author":"Pistilli","year":"2026","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.molmed.2026.09.014_bb0035","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.24.00720","article-title":"Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II LUMINOSITY trial","volume":"42","author":"Camidge","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2026.09.014_bb0040","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41586-026-10789-w","article-title":"Modular in vivo antibody-ADC click to reverse drug resistance in tumours","volume":"657","author":"Sim\u00f3","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2026.09.014_bb0045","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/s41586-024-07233-2","article-title":"TRBC1-targeting antibody-drug conjugates for the treatment of T cell cancers","volume":"628","author":"Nichakawade","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2026.09.014_bb0050","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1038\/s43018-025-01069-z","article-title":"TRBC2-targeting antibody-drug conjugates for the treatment of T cell cancers","volume":"6","author":"Ge","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.molmed.2026.09.014_bb0055","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.molmed.2026.09.014_bb0060","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.molmed.2026.09.014_bb0065","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody-drug conjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.molmed.2026.09.014_bb0070","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41568-025-00817-8","article-title":"Targeted protein degradation for cancer therapy","volume":"25","author":"Hinterndorfer","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.molmed.2026.09.014_bb0075","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","article-title":"Targeted protein degradation: mechanisms, strategies and application","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.molmed.2026.09.014_bb0080","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.molmed.2026.09.014_bb0085","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41573-023-00833-z","article-title":"Extracellular targeted protein degradation: an emerging modality for drug discovery","volume":"23","author":"Wells","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.molmed.2026.09.014_bb0090","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41573-019-0047-y","article-title":"Targeted protein degradation: expanding the toolbox","volume":"18","author":"Schapira","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.molmed.2026.09.014_bb0095","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.molmed.2026.09.014_bb0100","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2505725","article-title":"Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer","volume":"393","author":"Campone","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2026.09.014_bb0105","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1080\/14796694.2024.2377530","article-title":"VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+\/HER2\u2212 advanced breast cancer","volume":"20","author":"Hamilton","year":"2024","journal-title":"Future Oncol."},{"key":"10.1016\/j.molmed.2026.09.014_bb0110","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1038\/s41467-025-60107-7","article-title":"Linker-free PROTACs efficiently induce the degradation of oncoproteins","volume":"16","author":"Zhang","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2026.09.014_bb0115","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/j.cell.2026.01.018","article-title":"Hijacking ERAD for targeted degradation of transmembrane proteins","volume":"189","author":"Song","year":"2026","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2026.09.014_bb0120","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41586-024-07089-6","article-title":"Targeted protein degradation via intramolecular bivalent glues","volume":"627","author":"Hsia","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2026.09.014_bb0125","article-title":"A bivalent molecular glue linking lysine acetyltransferases to oncogene-induced cell death","author":"Nix","year":"2026","journal-title":"bioRxiv"},{"key":"10.1016\/j.molmed.2026.09.014_bb0130","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1126\/science.aef5391","article-title":"Degron-independent recruitment of KAT2A expands the target space of CRBN molecular glues","volume":"393","author":"Ojeda","year":"2026","journal-title":"Science"},{"key":"10.1016\/j.molmed.2026.09.014_bb0135","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41586-026-10613-5","article-title":"Molecular glue degraders of HuR suppress BRAF-mutant colorectal cancer","volume":"655","author":"Lu","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2026.09.014_bb0140","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41589-021-00770-1","article-title":"LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation","volume":"17","author":"Ahn","year":"2021","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.molmed.2026.09.014_bb0145","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","article-title":"Lysosome-targeting chimaeras for degradation of extracellular proteins","volume":"584","author":"Banik","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2026.09.014_bb0150","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41586-022-05235-6","article-title":"Antibody targeting of E3 ubiquitin ligases for receptor degradation","volume":"610","author":"Marei","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2026.09.014_bb0155","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1021\/jacs.0c10008","article-title":"Development of antibody-based PROTACs for the degradation of the cell-surface immune checkpoint protein PD-L1","volume":"143","author":"Cotton","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.molmed.2026.09.014_bb0160","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41587-022-01456-2","article-title":"Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins","volume":"41","author":"Pance","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.molmed.2026.09.014_bb0165","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41586-024-07947-3","article-title":"Transferrin receptor targeting chimeras for membrane protein degradation","volume":"638","author":"Zhang","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2026.09.014_bb0170","doi-asserted-by":"crossref","first-page":"39912","DOI":"10.1021\/jacs.5c15047","article-title":"Hijacking extracellular targeted protein degrader-drug conjugates for enhanced drug delivery","volume":"147","author":"Zhao","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.molmed.2026.09.014_bb0175","doi-asserted-by":"crossref","first-page":"12583","DOI":"10.1021\/acs.jmedchem.6c00592","article-title":"Antibody-mediated delivery of BRM\/BRG1 protein degraders affords strong antitumor efficacy in multiple BRM-dependent non-small cell lung cancer xenograft models","volume":"69","author":"Baker Dockrey","year":"2026","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.molmed.2026.09.014_bb0180","doi-asserted-by":"crossref","first-page":"6510","DOI":"10.1016\/j.apsb.2025.09.009","article-title":"Rational engineering of degradation tail-driven CELMoD-antibody conjugates for precision malignancy therapy","volume":"15","author":"Guo","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.molmed.2026.09.014_bb0185","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/acschembio.0c00285","article-title":"Antibody-PROTAC conjugates enable HER2-dependent targeted protein degradation of BRD4","volume":"15","author":"Maneiro","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.molmed.2026.09.014_bb0190","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.molmed.2026.09.014_bb0195","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1152\/physrev.00039.2025","article-title":"Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond","volume":"106","author":"Cheung","year":"2026","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.molmed.2026.09.014_bb0200","doi-asserted-by":"crossref","first-page":"19871","DOI":"10.1021\/acs.jmedchem.5c01982","article-title":"Recent advances in peptide linkers for antibody-drug conjugates","volume":"68","author":"Li","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.molmed.2026.09.014_bb0205","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.ccell.2026.05.004","article-title":"Antibody-drug conjugates in precision oncology","volume":"44","author":"Pistilli","year":"2026","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molmed.2026.09.014_bb0210","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.cell.2026.04.016","article-title":"Navigating the clinical progress of antibody-drug conjugates: emerging opportunities and remaining challenges","volume":"189","author":"Conilh","year":"2026","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2026.09.014_bb0215","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","article-title":"The journey of antibody-drug conjugates: lessons learned from 40 years of development","volume":"14","author":"Colombo","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.molmed.2026.09.014_bb0220","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/1078-0432.CCR-23-1725","article-title":"Spatiotemporal quantification of HER2-targeting antibody-drug conjugate bystander activity and enhancement of solid tumor penetration","volume":"30","author":"Wei","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2026.09.014_bb0225","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1158\/2159-8290.CD-20-1557","article-title":"Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab","volume":"11","author":"Filho","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.molmed.2026.09.014_bb0230","doi-asserted-by":"crossref","first-page":"674","DOI":"10.3390\/ph14070674","article-title":"Impact of endocytosis mechanisms for the receptors targeted by the currently approved antibody-drug conjugates (ADCs)\u2014a necessity for future ADC research and development","volume":"14","author":"Hammood","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.molmed.2026.09.014_bb0235","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.canlet.2022.01.003","article-title":"Inhibition of the endosomal recycling pathway downregulates HER2 activation and overcomes resistance to tyrosine kinase inhibitors in HER2-positive breast cancer","volume":"529","author":"Mishra","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.molmed.2026.09.014_bb0240","article-title":"SNX10 deficiency impairs sensitivity to anti-HER2 antibody-drug conjugates via altering HER2 trafficking in HER2-positive breast cancer","volume":"122","author":"Chen","year":"2025","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2026.09.014_bb0245","article-title":"Rab25-mediated EGFR recycling causes tumor acquired radioresistance","volume":"23","author":"Zhang","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.molmed.2026.09.014_bb0250","article-title":"A CMTM6 nanobody overcomes EGFR-TKI resistance in non-small cell lung cancer","volume":"12","author":"Xia","year":"2025","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.molmed.2026.09.014_bb0255","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12494","article-title":"RAB22A sorts epithelial growth factor receptor (EGFR) from early endosomes to recycling endosomes for microvesicles release","volume":"13","author":"Lin","year":"2024","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.molmed.2026.09.014_bb0260","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41420-025-02289-z","article-title":"Helicobacter pylori reduces METTL14-mediated VAMP3 m(6)A modification and promotes the development of gastric cancer by regulating LC3C-mediated c-Met recycling","volume":"11","author":"Cui","year":"2025","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.molmed.2026.09.014_bb0265","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.ccell.2026.04.010","article-title":"Endocytic evasion confers resistance to antibody-drug conjugates therapy in cancer","volume":"44","author":"Wang","year":"2026","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molmed.2026.09.014_bb0270","first-page":"1942","article-title":"Alternative splicing generates HER2 isoform diversity underlying antibody-drug conjugate resistance in breast cancer","volume":"35","author":"Guardia","year":"2025","journal-title":"Genome Res."},{"key":"10.1016\/j.molmed.2026.09.014_bb0275","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.apsb.2024.12.036","article-title":"Resistance to antibody-drug conjugates: a review","volume":"15","author":"Li","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.molmed.2026.09.014_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101086","article-title":"Spotlight on ideal target antigens and resistance in antibody-drug conjugates: strategies for competitive advancement","volume":"75","author":"Jiang","year":"2024","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.molmed.2026.09.014_bb0285","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1200\/JCO.21.01626","article-title":"Targeted therapies for lung cancer patients with oncogenic driver molecular alterations","volume":"40","author":"Tan","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2026.09.014_bb0290","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1158\/2159-8290.CD-21-0702","article-title":"Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer","volume":"11","author":"Coates","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.molmed.2026.09.014_bb0295","first-page":"833","article-title":"Drug resistance to antibody-drug conjugates: mechanisms, challenges, and perspectives","volume":"23","author":"Liu","year":"2026","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.molmed.2026.09.014_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2026.103711","article-title":"Targeting MET in EGFR-mutated NSCLC","volume":"21","author":"Saw","year":"2026","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.molmed.2026.09.014_bb0305","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/2159-8290.CD-21-0715","article-title":"Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer","volume":"12","author":"J\u00e4nne","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.molmed.2026.09.014_bb0310","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2026.09.014_bb0315","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-20-4175","article-title":"Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin","volume":"27","author":"Chu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2026.09.014_bb0320","doi-asserted-by":"crossref","DOI":"10.1038\/s41587-026-03302-1","article-title":"Macropinocytosis-mediated recyclable LYTACs (McR-TACs) for receptor-independent protein degradation","author":"Liu","year":"2026","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.molmed.2026.09.014_bb0325","doi-asserted-by":"crossref","DOI":"10.1126\/science.adx5094","article-title":"Targeted protein degradation in the transmembrane and extracellular space","volume":"390","author":"Zhu","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.molmed.2026.09.014_bb0330","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/s41586-024-07948-2","article-title":"Designed endocytosis-inducing proteins degrade targets and amplify signals","volume":"638","author":"Huang","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2026.09.014_bb0335","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1038\/s41589-025-01924-1","article-title":"Polyvalent folate receptor-targeting chimeras for degradation of membrane proteins","volume":"21","author":"Xiao","year":"2025","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.molmed.2026.09.014_bb0340","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/s41589-024-01803-1","article-title":"Chemically engineered antibodies for autophagy-based receptor degradation","volume":"21","author":"Cheng","year":"2025","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.molmed.2026.09.014_bb0345","first-page":"127","article-title":"Affinity-optimized TROP2 antibodies support potent antitumor activity in antibody-drug conjugates","volume":"9","author":"Yamaguchi","year":"2026","journal-title":"Antib. Ther."},{"key":"10.1016\/j.molmed.2026.09.014_bb0350","doi-asserted-by":"crossref","first-page":"9687","DOI":"10.1038\/s41467-025-64675-6","article-title":"Site-specific ligase-dependent conjugation with ring-opening linker improves safety and stability of HER2-targeting ADCs","volume":"16","author":"Huang","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2026.09.014_bb0355","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.apsb.2025.11.008","article-title":"Antibody\u2013drug conjugates with DHODH inhibitor as novel payload class for cancer and SARS-CoV-2 infection therapies","volume":"16","author":"Liu","year":"2026","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.molmed.2026.09.014_bb0360","article-title":"Recent advances in function-enhanced antibody-drug conjugates: antibody optimization and payload combination","author":"Liu","year":"2026","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.molmed.2026.09.014_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116216","article-title":"What influences the activity of degrader-antibody conjugates (DACs)","volume":"268","author":"Guo","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.molmed.2026.09.014_bb0370","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/cmdc.201900497","article-title":"Antibody conjugation of a chimeric BET degrader enables in vivo activity","volume":"15","author":"Pillow","year":"2020","journal-title":"ChemMedchem"},{"key":"10.1016\/j.molmed.2026.09.014_bb0375","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1039\/D2CS00141A","article-title":"Degrader-antibody conjugates","volume":"51","author":"Dragovich","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.molmed.2026.09.014_bb0380","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.tips.2025.04.002","article-title":"Molecular glue meets antibody: next-generation antibody-drug conjugates","volume":"46","author":"Tao","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.molmed.2026.09.014_bb0385","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1158\/1538-7445.AM2022-3933","article-title":"ORM-5029: a first-in-class targeted protein degradation therapy using antibody neodegrder conjugate (AnDC) for HER2-expressing breast cancer","volume":"82","author":"Palacino","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2026.09.014_bb0390","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1182\/blood-2022-168936","article-title":"ORM-6151: a first-in-class, anti-CD33 antibody-enabled GSPT1 degrader for AML","volume":"140","author":"Palacino","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2026.09.014_bb0395","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1158\/1538-7445.AM2026-1710","article-title":"ORM-1153: a novel CD123-targeting degrader antibody conjugate with proprietary GSPT1 degrading payload for the treatment of acute myeloid leukemia","volume":"86","author":"Choi","year":"2026","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2026.09.014_bb0400","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1158\/1538-7445.AM2026-1662","article-title":"GSPT1 degrader antibody conjugate, BLB-201, for the treatment of high-risk acute myeloid leukemia","volume":"86","author":"Bam","year":"2026","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2026.09.014_bb0405","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1158\/1538-7445.AM2026-2405","article-title":"A first-in-class IKZF1\/3 degrader antibody conjugate (DAC) as a potential myeloma treatment","volume":"86","author":"Wu","year":"2026","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2026.09.014_bb0410","article-title":"DAC-002, a novel IKZF1\/3 MGD-CD38 degrader-antibody conjugate for MM treatment","volume":"86","author":"Wang","year":"2026","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2026.09.014_bb0415","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1158\/1538-7445.AM2026-4394","article-title":"In vivo characterization of a PLK1 degrader antibody conjugate for treatment of DXd and MMAE refractory tumors","volume":"86","author":"Uitdehaag","year":"2026","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2026.09.014_bb0420","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1158\/1538-7445.AM2026-450","article-title":"JZY-2233: an antigen-targeted CBP\/p300 degrader-antibody conjugate for advanced prostate cancer therapy","volume":"86","author":"Wang","year":"2026","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2026.09.014_bb0425","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1158\/1538-7445.AM2026-1668","article-title":"MAC-8001: a KRAS-targeting molecular glue-antibody conjugate with robust antitumor activity in KRAS-mutant cancers","volume":"86","author":"Sun","year":"2026","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2026.09.014_bb0430","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.1158\/1538-7445.AM2025-7005","article-title":"Discovery and characterization of DAC-1522, a novel Trop2-targeting degrader-antibody conjugate for precision oncology","volume":"85","author":"Chen","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2026.09.014_bb0435","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-LB209","article-title":"An ADC composed of daratumumab and lenalidomide is extremely powerful in killing multiple myeloma cells","volume":"83","author":"Yu","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2026.09.014_bb0440","doi-asserted-by":"crossref","first-page":"15996","DOI":"10.1021\/acs.jmedchem.4c01289","article-title":"The new frontier: merging molecular glue degrader and antibody-drug conjugate modalities to overcome strategic challenges","volume":"67","author":"Poudel","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.molmed.2026.09.014_bb0445","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1038\/s41591-026-04543-y","article-title":"The next generation of antibody-drug conjugates","volume":"32","author":"Mosele","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2026.09.014_bb0450","doi-asserted-by":"crossref","first-page":"26218","DOI":"10.1021\/acs.jmedchem.5c02262","article-title":"Degrader-Drug Conjugate (DDC) mediated immunochemotherapy for tumor treatment","volume":"68","author":"Chen","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.molmed.2026.09.014_bb0455","article-title":"A plug-and-play platform for customizing multivalent degraders and degrader-drug conjugates","volume":"13","author":"Zhao","year":"2026","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.molmed.2026.09.014_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbpa.2026.102727","article-title":"Recent advances in antibody-drug conjugates","volume":"94","author":"Sydenham","year":"2026","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.molmed.2026.09.014_bb0465","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc8697","article-title":"Targeting a neoantigen derived from a common TP53 mutation","volume":"371","author":"Hsiue","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.molmed.2026.09.014_bb0470","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abd5515","article-title":"Bispecific antibodies targeting mutant RAS neoantigens","volume":"6","author":"Douglass","year":"2021","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.molmed.2026.09.014_bb0475","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.biomaterials.2018.06.017","article-title":"Elimination of melanoma by sortase A-generated TCR-like antibody-drug conjugates (TL-ADCs) targeting intracellular melanoma antigen MART-1","volume":"178","author":"Lai","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.molmed.2026.09.014_bb0480","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.3390\/ijms20163912","article-title":"The antitumor activity of TCR-mimic Antibody-drug conjugates (TCRm-ADCs) targeting the intracellular Wilms tumor 1 (WT1) oncoprotein","volume":"20","author":"Shen","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molmed.2026.09.014_bb0485","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13045-026-01807-5","article-title":"CD20-directed antibody-drug conjugates in non-Hodgkin lymphoma: translating preclinical promise into clinical reality","volume":"19","author":"Omidvar","year":"2026","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.molmed.2026.09.014_bb0490","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2524129123","article-title":"A cytokine receptor-targeting chimera toolbox for expanding extracellular targeted protein degradation","volume":"123","author":"Kumru","year":"2026","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2026.09.014_bb0495","doi-asserted-by":"crossref","first-page":"7171","DOI":"10.1021\/jacs.5c18594","article-title":"Development of prostate-specific lysosome-targeting degraders","volume":"148","author":"Cai","year":"2026","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.molmed.2026.09.014_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114344","article-title":"Novel single-domain antibodies targeting a unique transferrin receptor 1 epitope for cross-species delivery of drugs in the central nervous system","volume":"388","author":"David","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.molmed.2026.09.014_bb0505","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1021\/jacsau.5c01216","article-title":"PSMA-targeting chimeras for cell-type-specific degradation of surface immune checkpoint protein PD-L1","volume":"6","author":"Luo","year":"2026","journal-title":"JACS Au"},{"key":"10.1016\/j.molmed.2026.09.014_bb0510","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1021\/acschembio.2c00185","article-title":"Roadmap for optimizing and broadening antibody-based PROTACs for degradation of cell surface proteins","volume":"17","author":"Gramespacher","year":"2022","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.molmed.2026.09.014_bb0515","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41568-025-00869-w","article-title":"Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment","volume":"25","author":"Zippelius","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.molmed.2026.09.014_bb0520","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009710","article-title":"Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses","volume":"12","author":"Dong","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.molmed.2026.09.014_bb0525","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/s41467-024-46167-1","article-title":"Delivery of a BET protein degrader via a CEACAM6-targeted antibody-drug conjugate inhibits tumour growth in pancreatic cancer models","volume":"15","author":"Nakazawa","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2026.09.014_bb0530","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.chembiol.2026.02.015","article-title":"Receptor-ubiquitination-targeting antibody-drug conjugates for enhanced endocytosis and lysosomal delivery","volume":"33","author":"Zhuang","year":"2026","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.molmed.2026.09.014_bb0535","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1158\/1538-7445.AM2026-1725","article-title":"Dual modality of EpiTAC bispecific degrader ADCs combines c-MET degradation with cytotoxic payload delivery to overcome limitations of current c-MET-targeted therapies","volume":"86","author":"Marshall","year":"2026","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2026.09.014_bb0540","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.chembiol.2026.03.007","article-title":"A nature-inspired nanoplatform for multi-protein targeted degradation via the autophagy-lysosome pathway","volume":"33","author":"Tong","year":"2026","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.molmed.2026.09.014_bb0545","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1038\/s41467-022-31141-6","article-title":"Ursodeoxycholic acid reduces antitumor immunosuppression by inducing CHIP-mediated TGF-\u03b2 degradation","volume":"13","author":"Shen","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2026.09.014_bb0550","article-title":"ZBTB11 depletion targets metabolic vulnerabilities in K-RAS inhibitor resistant PDAC","author":"Tran","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.molmed.2026.09.014_bb0555","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41586-025-09000-3","article-title":"STAT5 and STAT3 balance shapes dendritic cell function and tumour immunity","volume":"643","author":"Zhou","year":"2025","journal-title":"Nature"}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491426002303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491426002303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T07:01:34Z","timestamp":1792393294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491426002303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":111,"alternative-id":["S1471491426002303"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2026.09.014","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Degradation-coupled antibody conjugates for precision cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2026.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}